We're coming to the end of January as we set our sights on Feb and the remaining Q1 events. We have a number of readouts coming including GTHX phase 3 data in Feb, ASCO-GU meeting mid Feb, and lots of Alzheimer's readouts throughout the year. The table below highlights catalysts coming in the next few weeks to keep an eye on. Connect with us and fellow traders in our Discord chat.
BPIQ Weekly Catalyst Watchlist Table:
Weekly Watchlist Highlights:
Viking has phase 1 data for the study of VK2735 treating metabolic disorder expected early 2023. Become a pro member to get full details.
Atreca expects to present updated monotherapy and combination data from the trial in the first quarter of 2023. Become a pro member to get full details.
REGN has a PDUFA date February 11, 2023 for their drug EYLEA (aflibercept) for retinopathy of prematurity (ROP) in preterm infants. Become a pro member to get full details.
